Latest Pharma and Biotech News
Biotechnology
11 December 2024 San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema.
Today's issue
Refine Search
Pharmaceutical
Swiss healthcare manufacturing organization Lonza saw its shares rise 7% to 559.40 francs in early trading, as it announced an overview of its strategy and new organizational structure at its Investor Update 2024. 12 December 2024
Biotechnology
Accent Therapeutics, a targeted cancer drug specialist, has announced the appointment of Serena Silver as chief scientific officer, as current CSO and co-founder Robert Copeland retires. 11 December 2024
Biotechnology
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema. 11 December 2024
Pharmaceutical
Lynparza (olaparib) partners AstraZeneca and Merck & Co have reported updated findings from the Phase III OlympiA trial in breast cancer, showing a sustained survival benefit. 11 December 2024
Biotechnology
Merck KGaA has appointed Miguel Fernández Alcalde as president of its US biopharmaceutical business, EMD Serono. 11 December 2024
Pharmaceutical
Minoryx Therapeutics, a Spanish biotech specializing in therapies for orphan CNS disorders, will submit for European approval for leriglitazone by the middle of next year. 11 December 2024
Pharmaceutical
Swiss specialty pharmaceutical company Santhera Pharmaceuticals has received approval from the National Medical Products Administration in China for Agamree (vamorolone). 11 December 2024
Biotechnology
Shares of US clinical stage biopharma Candel Therapeutics leapt 166% to $12.25 in pre-market activity today, after it announced results from a multicenter Phase III clinical trial evaluating its CAN-2409 viral immunotherapy in localized prostate cancer patients. 11 December 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has recently become the first Indian company to launch checkpoint inhibitor Zytorvi (toripalimab) in collaboration with Shanghai Junshi Biosciences . 11 December 2024
Biotechnology
US biotech Cardiff Oncology has announced positive initial data from CRDF-004, a randomized, Phase II trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). 11 December 2024
Biotechnology
Netherlands-based Pharming Group today released positive top-line results of data from its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). 11 December 2024
Biotechnology
Noema Pharma, a Swiss biotech targeting debilitating central nervous system (CNS) disorders, has announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences. 11 December 2024
Pharmaceutical
Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research results for its cholesterol lower obicetrapib. 11 December 2024
Biotechnology
Boston, USA-based biotech Tasca Therapeutics yesterday announced a $52 million Series A financing, co-led by Regeneron Ventures and Cure Ventures, with participation by Invus Group. 11 December 2024
Biotechnology
Bristol Myers Squibb has presented data on its cell therapy products at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California. 10 December 2024
Biotechnology
BeiGene has sought to underscore its leading position in the chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) space at the American Society of Hematology (ASH) Annual Meeting and Exposition. 10 December 2024
Biotechnology
Cambridge, USA-based Eikonizo Therapeutics today revealed it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative. 10 December 2024
Biotechnology
US biotech Nektar Therapeutics has announced results of its Phase II proof-of-concept study of NKTR-255 as an adjuvant treatment to enhance complete response rate (CRR) and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). 10 December 2024
Biotechnology
Dutch gene therapy company uniQure saw its shares rocket 86% to $13.57 today, after it reached agreement with the US Food and Drug Administration (FDA) on key elements of an Accelerated Approval pathway for AMT-130 in Huntington’s disease. 10 December 2024
Biotechnology
Newly presented data at the American Society of Hematology (ASH) annual meeting highlight significant clinical benefits for Sanofi’s Sarclisa (isatuximab) in multiple myeloma. 10 December 2024
All news
Pharmaceutical
Swiss healthcare manufacturing organization Lonza saw its shares rise 7% to 559.40 francs in early trading, as it announced an overview of its strategy and new organizational structure at its Investor Update 2024. 12 December 2024
Biotechnology
Accent Therapeutics, a targeted cancer drug specialist, has announced the appointment of Serena Silver as chief scientific officer, as current CSO and co-founder Robert Copeland retires. 11 December 2024
Biotechnology
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema. 11 December 2024
Pharmaceutical
Lynparza (olaparib) partners AstraZeneca and Merck & Co have reported updated findings from the Phase III OlympiA trial in breast cancer, showing a sustained survival benefit. 11 December 2024
Biotechnology
Merck KGaA has appointed Miguel Fernández Alcalde as president of its US biopharmaceutical business, EMD Serono. 11 December 2024
Pharmaceutical
Minoryx Therapeutics, a Spanish biotech specializing in therapies for orphan CNS disorders, will submit for European approval for leriglitazone by the middle of next year. 11 December 2024
Pharmaceutical
Swiss specialty pharmaceutical company Santhera Pharmaceuticals has received approval from the National Medical Products Administration in China for Agamree (vamorolone). 11 December 2024
Biotechnology
Shares of US clinical stage biopharma Candel Therapeutics leapt 166% to $12.25 in pre-market activity today, after it announced results from a multicenter Phase III clinical trial evaluating its CAN-2409 viral immunotherapy in localized prostate cancer patients. 11 December 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has recently become the first Indian company to launch checkpoint inhibitor Zytorvi (toripalimab) in collaboration with Shanghai Junshi Biosciences . 11 December 2024
Biotechnology
US biotech Cardiff Oncology has announced positive initial data from CRDF-004, a randomized, Phase II trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). 11 December 2024
Biotechnology
Netherlands-based Pharming Group today released positive top-line results of data from its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). 11 December 2024
Biotechnology
Noema Pharma, a Swiss biotech targeting debilitating central nervous system (CNS) disorders, has announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences. 11 December 2024
Pharmaceutical
Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research results for its cholesterol lower obicetrapib. 11 December 2024
Biotechnology
Boston, USA-based biotech Tasca Therapeutics yesterday announced a $52 million Series A financing, co-led by Regeneron Ventures and Cure Ventures, with participation by Invus Group. 11 December 2024
Biotechnology
Bristol Myers Squibb has presented data on its cell therapy products at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California. 10 December 2024
Biotechnology
BeiGene has sought to underscore its leading position in the chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) space at the American Society of Hematology (ASH) Annual Meeting and Exposition. 10 December 2024
Biotechnology
Cambridge, USA-based Eikonizo Therapeutics today revealed it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative. 10 December 2024
Biotechnology
US biotech Nektar Therapeutics has announced results of its Phase II proof-of-concept study of NKTR-255 as an adjuvant treatment to enhance complete response rate (CRR) and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). 10 December 2024
Biotechnology
Dutch gene therapy company uniQure saw its shares rocket 86% to $13.57 today, after it reached agreement with the US Food and Drug Administration (FDA) on key elements of an Accelerated Approval pathway for AMT-130 in Huntington’s disease. 10 December 2024
Biotechnology
Newly presented data at the American Society of Hematology (ASH) annual meeting highlight significant clinical benefits for Sanofi’s Sarclisa (isatuximab) in multiple myeloma. 10 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze